EVG-COBI-TAF-FTC versus EVG-COBI-TDF-FTC

GS-292-0102 Study
# EVG-COBI-TAF-FTC versus EVG-COBI-TDF-FTC

**GS-292-102 Study: Design**

## Study Design: GS-292-0102

**Background:** Randomized, double-blind, phase 2 trial comparing elvitegravir-cobicistat-tenofovir alafenamide-emtricitabine with elvitegravir-cobicistat-tenofovir DF-emtricitabine

**Inclusion Criteria (n = 171 randomized)**
- Antiretroviral-naïve adults
- Age ≥18
- HIV RNA ≥5000 copies/mL
- CD4 count >50 cells/mm³
- Estimated GFR ≥70 mL/min
- No AIDS conditions in prior 30 days
- Excluded if coinfected with HBV or HCV

**Treatment Arms**
- Elvitegravir-Cobicistat-TAF-FTC
- Elvitegravir-Cobicistat-TDF-FTC

- **EVG-COBI-TAF-FTC** *(Genvoya)*  
  (n = 112)  
  ![2x](image1.png)

- **EVG-COBI-TDF-FTC** *(Stribild)*  
  (n = 58)  
  ![1x](image2.png)

EVG-COBI-TAF-FTC versus EVG-COBI-TDF-FTC
GS-292-102 Study: Results

Week 24 and 48 Virologic Response (Snapshot Analysis)

Conclusions: “Treatment-naive patients given the STR that contained either TAF or TDF achieved a high rate of virologic success. Compared with those receiving TDF, patients on E/C/F/TAF experienced significantly smaller changes in estimated creatinine clearance, renal tubular proteinuria, and bone mineral density.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*